• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

Chlorinated lipids predict lung injury and death in sepsis patients

Bioengineer.org by Bioengineer.org
January 31, 2018
in Headlines, Health, Science News
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Saint Louis University / Ellen Hutti

ST. LOUIS — In a study published in the Journal of Clinical Investigation Insight, Saint Louis University scientists have found that elevated levels of chlorinated lipids are linked to sepsis, lung injury and death. The finding may offer a way to diagnosis and treat sepsis earlier, saving lives and avoiding serious side effects.

Sepsis is a dangerous immune response to an infection in which the whole body becomes inflamed. Most of the body's infections are local, sealed off and kept within the boundaries of an organ or part of the body, like the lungs or sinuses. In some cases, however, an untreated infection spreads and causes overwhelming systemic inflammation throughout the body.

Adults and children of every age can develop sepsis. It carries a high mortality rate as well as high risk of complications from massive drops in blood pressure and organ failure. The key challenge in treating sepsis is to diagnosis it and begin antibiotics quickly; as organs begin to shut down, treating sepsis becomes a matter of beating the clock.

In 2002, David Ford, Ph.D., professor of biochemistry and molecular biology at Saint Louis University, made a discovery of a type of lipid that had not previously been identified in humans.

"My lab discovered chlorinated lipids," Ford said. "They are made in the body under conditions where there is inflammation."

Ford's team, together with Jane McHowat, Ph.D., professor of pathology at SLU, have continued their study of chlorinated lipids and inflammation to better understand the link between the two.

In the study described in the Journal of Clinical Investigation Insight paper, researchers examined blood samples taken soon after admission to the hospital from patients who were eventually diagnosed with sepsis.

They found that chlorinated lipids not only were present in the blood but that they also predicted whether a patient would go on to suffer acute respiratory distress symptom (ARDS) and predicted whether patients would die within 30 days from a lung injury.

"Chlorinated lipids appear to serve as a very early warning sign that a patient is on track for a severe lung injury that could be fatal," Ford said.

Investigators had learned that elevated levels of chlorinated lipids could serve as a biomarker, a sign post that appeared when the body became inflamed. But, they also wondered if chlorinated lipids were the culprit causing the inflammation.

"There is another layer to this research: Are chlorinated lipids a causative agent?

"We examined this at a basic science level," Ford said. "Our research suggests that they do cause injury in the microcirculation of the lung. The data in this paper suggests chlorinated lipids have a causative role."

Researchers found that chlorinated lipids are generated by enzymes in neutrophils, a type of white blood cell. When the body is fighting an infection, neutrophils kill microbes. In the process of fighting off the intruder, chlorinated lipids are generated as a by-product. They are the collateral damage that occurs to a patient's own tissue by its immune system.

In a second paper, published in the Journal of Lipid Research, Ford and his collaborators explored the mechanisms of how this process works.

Celine Hartman, a SLU graduate student, made an analog (similar form) of a chlorinated lipid. That allowed the research team to track where the lipid travels within the endothelial cells in the linings of blood and lymph vessels.

"What Celine found was that the analog goes very specifically to a granule within an endothelial cell, called a Weibel-Palade body," Ford said. "That is significant because Weibel-Palade bodies contain proteins that are responsible for inflammation at the site where blood interfaces with the small blood vessels of an organ, the microcirculation, which is associated with organ injury and edema."

The findings in these papers set the stage for two strategies against sepsis.

First, if researchers can develop a rapid test for chlorinated fatty acids in the clinic, they could begin treatment sooner and buy time for patients.

"Right now, the only treatment for sepsis is antibiotics," Ford said. "The faster a patient is put on them, the greater survival and fewer side effects. There have been studies showing that the faster antibiotics are administered after hospital admission, the better the patient's outcome."

Second, if chlorinated lipids are indeed causative as Ford's data suggests, then molecules could be developed to block their action, leading to a potential new therapy to stop sepsis-caused organ injury and death.

###

Researchers on the Journal of Clinical Investigation Insight paper include Nuala J. Meyer, John P. Reilly, Rui Feng, Jason D. Christie, Stanley L. Hazen, Carolyn J. Albert, Jacob D. Franke, Celine L. Hartman, Jane McHowat, and David A. Ford.

Researchers on the Journal of Lipid Research paper include Celine L. Hartman, Mark A. Duerr, Carolyn J. Albert, William L. Neumann, Jane McHowat, and David A. Ford.

The research was funded by the National Institutes of Health (grants R01GM115553, R01HL122474, P01HL076491, and R01GM115552) and the American Heart Association Grant-in-Aid 15GRNT25750022.

Saint Louis University School of Medicine

Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: cancer, liver disease, heart/lung disease, aging and brain disease, and infectious diseases.

Media Contact

Carrie Bebermeyer
[email protected]
314-977-8015
@SLU_Official

http://www.slu.edu

Original Source

https://www.slu.edu/news/2018/january/sepsis-research.php http://dx.doi.org/10.1172/jci.insight.96432

Share24Tweet8Share2ShareShareShare2

Related Posts

Lymph Node Subtypes Reveal Colorectal Cancer Insights

Lymph Node Subtypes Reveal Colorectal Cancer Insights

August 22, 2025
Boosted Growth in Preterm Infants via Protein-Fortified Milk

Boosted Growth in Preterm Infants via Protein-Fortified Milk

August 22, 2025

Nutrition Education Prevents Malnutrition in Radiotherapy

August 22, 2025

Scientists Unveil Breakthrough Technique for Large-Scale Metabolite Analysis in Biological Samples

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lymph Node Subtypes Reveal Colorectal Cancer Insights

Boosted Growth in Preterm Infants via Protein-Fortified Milk

Nutrition Education Prevents Malnutrition in Radiotherapy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.